Compare Unilever plc (UL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs Vertex Pharmaceuticals Incorporated — how do they compare? Unilever plc trades at $62.18 (market cap $131.86B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Unilever plc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Unilever plc pays a 3.68% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| UL | VRTX | |
|---|---|---|
Market Cap | $131.86B | $121.95B |
Sector | Consumer Staples | Health |
52-Week High | $74.59 | $529.59 |
52-Week Low | $55.05 | $366.54 |
Enterprise Value | $157.31B | $116.69B |
Dividend Yield | 3.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
